Physician profile
Stuart R Jones
NPI 1437228087
$5,820.83
in general payments reported to CMS, 2019-2025
49 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $626 · 2020: $161 · 2021: $1,202 · 2022: $1,067 · 2023: $948 · 2024: $741 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,712 · Education: $53.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,711.79 |
| Education | $53.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,196.91 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $542.25 | 2022-2025 | |
| Acessa Health INC. | $523.01 | 2021 | |
| Hologic Sales and Service, LLC | $360.60 | 2019-2022 | |
| Novo Nordisk INC | $316.06 | 2023-2025 | Wegovy |
| Astellas Pharma US INC | $306.00 | 2019-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $287.88 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $160.08 | 2019-2025 | Slynd |
| Aspira Women'S Health INC | $147.27 | 2022-2024 | Ova1 |
| Therapeuticsmd, INC. | $137.77 | 2019-2022 | |
| Pfizer INC. | $136.17 | 2019-2024 | |
| Organon LLC | $119.73 | 2022-2025 | Nexplanon, Jada System |
| Evofem Biosciences, INC. | $118.90 | 2021-2022 | |
| Agile Therapeutics, INC. | $112.05 | 2021-2024 | Twirla |
| Daiichi Sankyo INC. | $109.89 | 2021-2023 | Injectafer |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $109.20 | 2024-2025 | Intrarosa |
| Minerva Surgical, INC | $91.90 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.82 | 2019-2024 | |
| Biogen, INC. | $71.80 | 2024-2025 | Zurzuvae |
| Myriad Women'S Health, INC. | $65.67 | 2023 | Myrisk |
| Coopersurgical, INC. | $63.48 | 2022-2024 | Paragard T 380a |
| Biohaven Pharmaceutical Holding Company LTD. | $57.52 | 2022 | |
| Amgen INC. | $54.15 | 2019-2025 | Evenity, Prolia |
| Lupin INC. | $52.68 | 2021 | |
| Gynesonics, INC. | $51.81 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mylan Pharmaceuticals INC. | $48.32 | 2021 | |
| Scynexis, INC. | $44.60 | 2022 | |
| Allergan, INC. | $43.27 | 2019-2020 | |
| Roche Diagnostics Corporation | $38.50 | 2019 | |
| Lilly USA, LLC | $38.15 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $33.00 | 2025 | Cologuard Collection Kit |
| Optumhealth Care Solutions, LLC | $27.61 | 2025 | Vivify Health Care Team Portal 001, Eitan Medical |
| Takeda Pharmaceuticals U.S.A., INC. | $26.18 | 2019-2021 | |
| Shield Therapeutics INC | $20.17 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $19.79 | 2023 | Exparel |
| Coloplast Corp | $19.46 | 2022 | |
| Alydia Health | $19.38 | 2021 | |
| Myovant Sciences INC. | $17.50 | 2022 | |
| Smith+Nephew, INC. | $16.94 | 2022 | |
| Vertical Pharmaceuticals, LLC | $16.05 | 2019 | |
| Bausch Health US, LLC | $15.44 | 2019 | |
| Becton, Dickinson and Company | $15.27 | 2024 | Bd Onclarity |
| Currax Pharmaceuticals LLC | $14.91 | 2024 | Contrave |
| Lsi Solutions INC | $14.75 | 2023 | Fornisee |
| Medtronic, INC. | $13.33 | 2022 | |
| Amag Pharmaceuticals, INC. | $13.15 | 2019 | |
| Avion Pharmaceuticals | $11.90 | 2020 | |
| Alfasigma USA, INC. | $11.56 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.